cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Akebia Therapeutics Inc
57 own
63 watching
Current Price
$1.36
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
216.55M
52-Week High
52-Week High
2.48000
52-Week Low
52-Week Low
0.65000
Average Volume
Average Volume
2.58M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization216.55M
icon52-Week High2.48000
icon52-Week Low0.65000
iconAverage Volume2.58M
iconDividend Yield--
iconP/E Ratio--
What does the Akebia Therapeutics Inc do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Akebia Therapeutics Inc make?
News & Events about Akebia Therapeutics Inc.
PR Newswire
10 months ago
Thinking about buying stock in Oncolytics Biotech, VERSES AI, Akebia Therapeutics, Sigilon Therapeutics, or BlackBerry? Thinking about buying stock in Oncolytics Biotech, VERSES AI, Akebia Therapeutics, Sigilon Therapeutics, or BlackBerry? PR Newswire NEW YORK, June 29, 2023 NEW YORK, June 29, 2023...
Ticker Report
10 months ago
Akebia Therapeutics, Inc. (NASDAQ:AKBA Get Rating) was the target of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 5,150,000 shares, an increase of 26.5% from the May 15th total of 4,070,000 shares. Based on an average ...
Ticker Report
12 months ago
Akebia Therapeutics (NASDAQ:AKBA Get Rating) had its price target increased by equities research analysts at HC Wainwright from $1.25 to $2.00 in a research note issued on Wednesday, The Fly reports. HC Wainwrights price objective indicates a potential upside of 119.20% from the ...
PR Newswire
1 year ago
Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split PR Newswire CAMBRIDGE, Mass., April 14, 2023 Webcast Scheduled for Friday, April 21 at...
PR Newswire
1 year ago
Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders PR Newswire CAMBRIDGE, Mass., April 11, 2023 Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time CAMBRIDGE, Mass., April 11...
Frequently Asked Questions
Frequently Asked Questions
What is Akebia Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Akebia Therapeutics Inc shares?
plus_minus_icon
How can I buy Akebia Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Akebia Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Akebia Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Akebia Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Akebia Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Akebia Therapeutics Inc?
plus_minus_icon
What percentage is Akebia Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Akebia Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.36
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00